MAIA Biotechnology, Inc. Annual report pursuant to Section 13 and 15(d)

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2023

The Company's net deferred tax assets consist of the following components:


	December 31,
	2023			2022
Deferred tax assets:
Net operating loss carryforwards	$	5,226,712		$	3,294,955
Stock-based compensation		1,378,351			1,183,941
Research and development		3,183,980			1,499,300
Accrued compensation		584,001			244,848
Other		—			6,724
Total net deferred tax assets before valuation allowance		10,373,044			6,229,768
Valuation allowance		(10,373,044	)		(6,229,768	)
Net deferred tax asset	$	—		$	—

The income tax benefit differs from the benefit that would result from applying federal statutory rates to loss before income taxes as follows:


	December 31,
	2023			2022
Statutory federal income tax rate		21.0	%		21.0	%
State taxes, net of federal tax benefit		1.1	%		(7.7	)%
Stock-based compensation		(2.2	)%		(1.2	)%
Loss on extinguishment of debt		—	%		(1.5	)%
Other nondeductible expenses/(nontaxable income)		1.0	%		(3.0	)%
Change in valuation allowance		(20.9	)%		(7.6	)%
Income tax benefit		—	%		—	%